Massachusetts has stopped paying for GLP-1 weight-loss drugs such as Wegovy and Zepbound through MassHealth and the Group Insurance Commission, the state body that covers public employees, after the change took effect as part of Governor Maura Healey’s fiscal 2027 budget. State officials say the policy, which does not affect coverage for diabetes or other approved conditions, will save roughly $15 million a year for MassHealth alone, according to reporting on the budget change boston.com covered in June. The change is expected to affect at least 22,000 MassHealth members, many of whom qualify for coverage because of disability or low income.
The scale of the shift across Massachusetts health coverage is larger than the Medicaid cut alone. A Health Policy Commission report found that 112,000 fewer commercially insured residents used a GLP-1 drug for weight loss between the end of 2025 and the first quarter of 2026, a 52 percent decline tied to coverage changes at Blue Cross Blue Shield of Massachusetts, Point32Health, and other private insurers, according to GBH’s account of the commission’s figures. Blue Cross told reporters it spent $515 million on the drugs last year and was on pace to nearly double that spending before changing its policy.
Officials say the drug prices are unsustainable
Dr. Ryan Schwarz, assistant secretary for the state’s Medicaid program, has acknowledged publicly that the policy restricts access for people least able to pay out of pocket, but said the list prices of the drugs are, in his words, ridiculous, according to reporting carried in a joint account of the policy fight. Wegovy carries a list price above $1,300 a month and Zepbound around $1,000, though manufacturer discount programmes can lower out-of-pocket costs to roughly $350 to $500 a month for some patients. Schwarz has said the state hopes to restore coverage if drug pricing changes make it sustainable again.
Critics argue the state’s own data undercuts the affordability argument it is making. The Health Policy Commission found that commercial market spending on the drugs would fall by 32 to 61 percent if insurers paid prices negotiated by Medicare or benchmarked to international reference prices, a comparison reported by GBH. That suggests the state is responding to list prices set by manufacturers rather than to the actual cost of delivering the drugs, a distinction advocates say gets lost when officials describe the cuts purely as a matter of fiscal necessity.
Physicians who treat obesity have pushed back hardest on the equity framing the state itself rarely uses. Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women’s Hospital, said insurers are engaging in what she called blatant bias and stigma against people with obesity, according to boston.com. A separate report on the equity debate, drawing on statements from advocates and lawmakers, found that critics including civil-rights figures have asked the Healey administration to reconsider the policy on the grounds that the people losing coverage are disproportionately low-income and face higher obesity-related health risks, according to Stateaffairs.com.
Equity warnings reach the statehouse
Martin Luther King III has publicly urged Massachusetts officials to reconsider the coverage cut, framing it as a matter that touches on long-standing disparities in access to effective medical treatment, according to the reporting on the equity debate carried by statehousenews.com. The Boston Globe’s own coverage of the dispute, examining both the fiscal rationale and the equity objections raised by critics, noted that the state continues to cover the same drugs for patients with diabetes or sleep apnea while denying them to patients whose only diagnosis is obesity, a distinction the Globe’s reporting flagged as central to the equity complaint, per bostonglobe.com.
How the outlets framed it
Coverage of the equity complaints, including the account carried by statehousenews.com, framed the dispute around civil-rights language, describing the cuts as falling hardest on people already facing health disparities and quoting warnings from figures such as Martin Luther King III. The Health Policy Commission’s own figures and the Globe’s business-section reporting instead framed the same decision in budgetary terms, describing it as a cost-containment measure driven by the list prices manufacturers charge and the unsustainable growth in spending the state and private insurers were absorbing. The gap between the moral language used in public appeals and the line-item language used in budget documents and agency statements reveals how differently the same policy can be described depending on whether the audience is patients or legislators reviewing a balance sheet.
Massachusetts was one of roughly a dozen states that covered GLP-1 drugs for weight loss under Medicaid without requiring another qualifying diagnosis before this year’s rollback, according to research cited in reporting on the policy shift. Several other states have been pulling back coverage in parallel, suggesting the Massachusetts decision reflects a broader national retreat from GLP-1 coverage for weight loss across both public and private insurance rather than an isolated budget choice specific to the Healey administration.
